Alnylam Pharmaceuticals Inc. (ALNY)

71.14
NASDAQ : Health Technology
Prev Close 71.80
Day Low/High 70.62 / 72.98
52 Wk Low/High 60.27 / 124.22
Avg Volume 957.40K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.65B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias

Alnylam Reports Positive Initial Clinical Results For ALN-AS1, An Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today initial positive results from its ongoing Phase 1 clinical trial with ALN-AS1, an investigational RNAi therapeutic...

Alnylam To Webcast Presentations At Upcoming September Conferences

Alnylam To Webcast Presentations At Upcoming September Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Friday, September...

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has selected a Development Candidate (DC) for ALN-GO1, an investigational RNAi therapeutic targeting the...

3 High-Volume Stocks to Trade Now (or Not)

3 High-Volume Stocks to Trade Now (or Not)

Here's a technical look at some of the most active stocks on the market today.

Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

(Graphic: Business Wire)

(Graphic: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BGSF, CHMG, CRM, ELSE, GSAT, HNP, LYTS, SSFN Downgrades: ALNY, ASMI, BYBK, CBS.A, CPHD, GCO, INAP, INTU, IXYS, JMEI, MANT, MU, NX, PERY, SAFT, SSI, TSC, YPF Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The bulls can show them around the place.

Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)

Water-Logged And Getting Wetter: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Analysts' Actions -- Intel, Texas Instruments and Viacom

Analysts' Actions -- Intel, Texas Instruments and Viacom

Here are Friday's top research calls, including downgrades of Intel and Texas Insturments

Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)

Lagging In Post-Market Activity: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a post-market laggard candidate

Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2015, and highlighted recent progress in advancing its...

Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference

Alnylam To Webcast Presentation At Canaccord Genuity 35th Annual Growth Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 35 th Annual Growth conference on Wednesday,...

Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2015 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2015 on Thursday, August 6, 2015, after...

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Initiates Phase 1/2 Clinical Trial For ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi...

Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Initiates Phase 3 Open Label Extension Study ("APOLLO-OLE") With Patisiran, An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR Amyloidosis)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its Phase 3 open-label extension study (abbreviated "APOLLO-OLE") with patisiran, an...

Today's Stocks Driving Success For The Drugs Industry

Today's Stocks Driving Success For The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Alnylam To Reschedule First RNAi Roundtable Webcast

Alnylam To Reschedule First RNAi Roundtable Webcast

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that due to an unforeseen scheduling issue with its guest speaker, the first program in the company's series of RNAi...

Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series

Alnylam To Host Second Annual Summer "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast its annual summer series of online "RNAi Roundtables" this July, August, and...

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Is Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that new positive data from its ongoing Phase 1 clinical trial with ALN-AT3 - an investigational RNAi therapeutic for...

Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today

Alnylam Pharmaceuticals (ALNY) Weak On High Volume Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases

Alnylam Reports Positive Initial Clinical Results For ALN-CC5, An Investigational RNAi Therapeutic Targeting Complement Component C5 For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an investigational RNAi therapeutic...

Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals

Alnylam Files Trade Secret Misappropriation Suit Against Dicerna Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc.

Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer

Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, today announced the appointment of David-Alexandre "DA" Gros, M.

Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam To Present New Data At International Society On Thrombosis And Haemostasis (ISTH) 2015 Congress With ALN-AT3, An Investigational RNAi Therapeutic For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it will present new interim Phase 1 clinical data and additional pre-clinical study results on ALN-AT3 - an...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the following conferences in June: Jefferies 2015...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALNY, ATAI, DANG, ISSI, MTSI, TNP Downgrades: EMMS, EPIQ, IT, MSON, TFM Initiations: None Read on to get TheStreet Quant Ratings' detailed report: